Genetic fusions favor tumorigenesis through degron loss in oncogenes.
Liu J, Tokheim C, Lee JD, Gan W, North BJ, Liu XS, Pandolfi PP, Wei W.
Nat Commun. 2021 11 18. 12(1):6704. PMID: 34795215
Links
Overview
Collin Tokheim received his Ph.D. in Biomedical Engineering from Johns Hopkins University in 2018. During his Ph.D., his research focused on the development and application of novel computational methodologies to statistically implicate mutations underlying the development or progression of human cancers. He has expertise in machine learning, statistical modeling, genomics, and cancer genetics. Collin is now a Research Fellow at the Harvard School of Public Health and Dana-Farber Cancer Institute. Dr. Tokheim's current research focus is to understand how protein degradation is dysregulated in cancer and how this informs an emerging therapeutic paradigm of Targeted Protein Degradation (TPD) drugs. TPD drugs selectively and potently eliminate -- rather than inhibit -- disease causing proteins.
B.S., 04/2011, Biomedical Engineering
University of Iowa, Iowa City, IA
Ph.D., 12/2018, Biomedical Engineering
Johns Hopkins University, Baltimore, MD
Engineering Excellence Scholarship
University of Iowa
E. Lester and Frances M. Williams Fund Scholarship
University of Iowa
William C. Blackburn Engineering Scholarship
University of Iowa
National Cancer Institute (NCI) NRSA Fellowship
Martin and Carol Macht Award
Johns Hopkins University
Damon Runyon Quantitative Biology Fellowship
Damon Runyon Cancer Research Foundation
Emerging Leaders in Computational Oncology Award
Memorial Sloan Kettering
Bibliography
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y, Traugh N, Zeng Z, Zhang Y, Li Z, Zhang B, Fu J, Xiao T, Li W, Meyer CA, Chu J, Jiang P, Cejas P, Lim K, Long H, Brown M, Liu XS.
Cell. 2021 10 14. 184(21):5357-5374.e22. PMID: 34582788
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.
Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, Meyer C, Stewig B, Xie Y, Bu X, Manos MP, Font-Tello A, Gjini E, Lako A, Lim K, Conway J, Tewari AK, Zeng Z, Sahu AD, Tokheim C, Weirather JL, Fu J, Zhang Y, Kroger B, Liang JH, Cejas P, Freeman GJ, Rodig S, Long HW, Gewurz BE, Hodi FS, Brown M, Liu XS.
Cancer Discov. 2021 06. 11(6):1524-1541. PMID: 33589424
Systematic characterization of mutations altering protein degradation in human cancers.
Tokheim C, Wang X, Timms RT, Zhang B, Mena EL, Wang B, Chen C, Ge J, Chu J, Zhang W, Elledge SJ, Brown M, Liu XS.
Mol Cell. 2021 03 18. 81(6):1292-1308.e11. PMID: 33567269
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.
Makohon-Moore AP, Lipson EJ, Hooper JE, Zucker A, Hong J, Bielski CM, Hayashi A, Tokheim C, Baez P, Kappagantula R, Kohutek Z, Makarov V, Riaz N, Postow MA, Chapman PB, Karchin R, Socci ND, Solit DB, Chan TA, Taylor BS, Topalian SL, Iacobuzio-Donahue CA.
Clin Cancer Res. 2021 03 01. 27(5):1516-1525. PMID: 33323400
Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network.
Zeng Z, Fu J, Cibulskis C, Jhaveri A, Gumbs C, Das B, Sanchez-Espiridion B, Janssens S, Taing L, Wang J, Lindsay J, Vilimas T, Zhang J, Tokheim C, Sahu A, Jiang P, Yan C, Duose DY, Cerami E, Chen L, Cohen D, Chen Q, Enos R, Huang X, Lee JJ, Liu Y, Neuberg DS, Nguyen C, Patterson C, Sarkar S, Shukla S, Tang M, Tsuji J, Uduman M, Wang X, Weirather JL, Yu J, Yu J, Zhang J, Zhang J, Meerzaman D, Thurin M, Futreal A, Karlovich C, Gabriel SB, Wistuba II, Liu XS, Wu CJ.
Clin Cancer Res. 2021 09 15. 27(18):5049-5061. PMID: 33323402
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade.
Gu SS, Wang X, Hu X, Jiang P, Li Z, Traugh N, Bu X, Tang Q, Wang C, Zeng Z, Fu J, Meyer C, Zhang Y, Cejas P, Lim K, Wang J, Zhang W, Tokheim C, Sahu AD, Xing X, Kroger B, Ouyang Z, Long H, Freeman GJ, Brown M, Liu XS.
Genome Biol. 2020 10 15. 21(1):263. PMID: 33059736
Determinants of transcription factor regulatory range.
Chen CH, Zheng R, Tokheim C, Dong X, Fan J, Wan C, Tang Q, Brown M, Liu JS, Meyer CA, Liu XS.
Nat Commun. 2020 05 18. 11(1):2472. PMID: 32424124
Integrated Informatics Analysis of Cancer-Related Variants.
Pagel KA, Kim R, Moad K, Busby B, Zheng L, Tokheim C, Ryan M, Karchin R.
JCO Clin Cancer Inform. 2020 03. 4:310-317. PMID: 32228266
High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
Shao XM, Bhattacharya R, Huang J, Sivakumar IKA, Tokheim C, Zheng L, Hirsch D, Kaminow B, Omdahl A, Bonsack M, Riemer AB, Velculescu VE, Anagnostou V, Pagel KA, Karchin R.
Cancer Immunol Res. 2020 03. 8(3):396-408. PMID: 31871119